Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Galapagos

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Galapagos. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-001279-34 Sponsor Protocol Number: GLPG1690-CL-206 Start Date*: 2019-08-20
    Sponsor Name:Galapagos NV
    Full Title: A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000719-30 Sponsor Protocol Number: GLPG0634-CL-341 Start Date*: 2022-08-30
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, controlled, multi-center study to evaluate the efficacy and safety of dose de-escalation of orally administered filgotinib in subjects with ulcerative colitis in clinica...
    Medical condition: ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) CZ (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001817-33 Sponsor Protocol Number: GLPG1690-CL-204 Start Date*: 2019-01-14
    Sponsor Name:Galapagos NV
    Full Title: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic...
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000659-11 Sponsor Protocol Number: GLPG3970-CL-210 Start Date*: 2020-09-10
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000545-52 Sponsor Protocol Number: GLPG0634-CL-225 Start Date*: 2017-10-06
    Sponsor Name:Galapagos Nv
    Full Title: A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001405-87 Sponsor Protocol Number: GLPG1690-CL-303 Start Date*: 2018-12-20
    Sponsor Name:Galapagos NV
    Full Title: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for mi...
    Medical condition: Idiopatic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002763-34 Sponsor Protocol Number: GS-US-419-3896 Start Date*: 2017-02-08
    Sponsor Name:Galapagos NV
    Full Title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Completed) SE (Completed) GR (Completed) PT (Completed) SK (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) NL (Completed) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001142-10 Sponsor Protocol Number: MOR106-CL-201 Start Date*: 2018-04-26
    Sponsor Name:Galapagos N.V.
    Full Title: A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with mo...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002837-31 Sponsor Protocol Number: GLPG2222-CL-201 Start Date*: 2016-12-02
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (cla...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001406-29 Sponsor Protocol Number: GLPG1690-CL-304 Start Date*: 2019-01-28
    Sponsor Name:Galapagos NV
    Full Title: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for mi...
    Medical condition: Idiopatic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003292-30 Sponsor Protocol Number: GLPG1837-CL-202 Start Date*: 2016-01-18
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation.
    Medical condition: Cystic fibrosis with the S1251N mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004157-41 Sponsor Protocol Number: GLPG1690­CL­202 Start Date*: 2016-03-21
    Sponsor Name:Galapagos NV
    Full Title: Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Adm...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003298-22 Sponsor Protocol Number: GLPG3970-CL-207 Start Date*: 2021-01-15
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ...
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) GR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003630-25 Sponsor Protocol Number: GS-US-417-0304 Start Date*: 2017-06-15
    Sponsor Name:Galapagos NV
    Full Title: A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Ongoing) BE (Ongoing) CZ (Ongoing) DE (Ongoing) PL (Ongoing) ES (Completed) BG (Ongoing) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003521-21 Sponsor Protocol Number: GLPG2737-CL-203 Start Date*: 2020-01-20
    Sponsor Name:Galapagos NV
    Full Title: An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, fol...
    Medical condition: Autosomal dominant polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003291-77 Sponsor Protocol Number: GLPG1837-CL-201 Start Date*: 2016-02-02
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation
    Medical condition: Cystic fibrosis with the G551D mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002181-42 Sponsor Protocol Number: GLPG2737-CL-202 Start Date*: 2017-10-27
    Sponsor Name:Galapagos NV
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000658-83 Sponsor Protocol Number: GLPG3970-CL-209 Start Date*: 2020-10-21
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004477-40 Sponsor Protocol Number: GLPG2222-CL-202 Start Date*: 2017-05-26
    Sponsor Name:Galapagos NV
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004302-18 Sponsor Protocol Number: GLPG1205-CL-220 Start Date*: 2018-06-18
    Sponsor Name:Galapagos NV
    Full Title: A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis.
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) FR (Completed) BG (Completed) FI (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 20:15:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA